Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus for recurrent implantation failure associated with immunologic factors
IRCT20160422027520N22Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Mar 2023
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tacrolimus in Recurrent Implantation Failure (RIF) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Pregnancy rate. Started Mar 2023; status: completed.
02
Drugs
tacrolimus
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on IRCT20160422027520N22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160422027520N22.